Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments.
algorithme
artificial pancreas
calcul des glucides
closed-loop systems
diabète de type 1
glucagon
insulin
insuline
optimisation
pancréas artificiel
pramlintide
systèmes en boucle fermée
type 1 diabetes
Journal
Canadian journal of diabetes
ISSN: 2352-3840
Titre abrégé: Can J Diabetes
Pays: Canada
ID NLM: 101148810
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
10
07
2020
revised:
11
02
2021
accepted:
14
02
2021
pubmed:
24
4
2021
medline:
14
1
2022
entrez:
23
4
2021
Statut:
ppublish
Résumé
A fully automated insulin-pramlintide-glucagon artificial pancreas that alleviates the burden of carbohydrate counting without degrading glycemic control was iteratively enhanced until convergence through pilot experiments on adults with type 1 diabetes. Nine participants (age, 37±13 years; glycated hemoglobin, 7.7±0.7%) completed two 27-hour interventions: a fully automated multihormone artificial pancreas and a comparator insulin-alone artificial pancreas with carbohydrate counting. The baseline algorithm was a model-predictive controller that administered insulin and pramlintide in a fixed ratio, with boluses triggered by a glucose threshold, and administered glucagon in response to low glucose levels. The baseline multihormone dosing algorithm resulted in noninferior time in target range (3.9 to 10.0 mmol/L) (71%) compared with the insulin-alone arm (70%) in 2 participants, with minimal glucagon delivery. The algorithm was modified to deliver insulin and pramlintide more aggressively to increase time in range and maximize the benefits of glucagon. The modified algorithm displayed a similar time in range for the multihormone arm (79%) compared with the insulin-alone arm (83%) in 2 participants, but with undesired glycemic fluctuations. Subsequently, we reduced the glucose threshold that triggers glucagon boluses. This resulted in inferior glycemic control for the multihormone arm (81% vs 91%) in 2 participants. Thereafter, a model-based meal-detection algorithm to deliver insulin and pramlintide boluses closer to mealtimes was added and glucagon was removed. The final dual-hormone system had comparable time in range (81% vs 83%) in the last 3 participants. The final version of the fully automated system that delivered insulin and pramlintide warrants a randomized controlled trial.
Identifiants
pubmed: 33888413
pii: S1499-2671(21)00045-9
doi: 10.1016/j.jcjd.2021.02.002
pii:
doi:
Substances chimiques
Blood Glucose
0
Hypoglycemic Agents
0
Insulin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
734-742Informations de copyright
Copyright © 2021 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.